MedTrace Logo

30g vs 33g Needle for Intravitreal Injections

NCT03038048 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-07-25

No results posted yet for this study

Summary

We are comparing the patient experience between the standard 30 g needle to the smaller 33 g needle for intravitreal injections of ranabizumab or aflibercept for age related macular degeneration, diabetic macular edema, or retina vein occlusions.

Conditions

Interventions

PROCEDURE

Varying needle size with intravitreal ranibizumab or aflibercept

Varying gauge of needle, 33 gauge vs 30 gauge

Sponsors & Collaborators

  • Mid Atlantic Retina

    collaborator OTHER

  • Wills Eye

    lead OTHER

Principal Investigators

  • Allen Chiang, MD · Mid Atlantic Retina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-27
Primary Completion
2017-04-27
Completion
2017-04-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03038048 on ClinicalTrials.gov